Surgical Innovations Group (LSE:SUN) Other Current Receivables: £0.12 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Surgical Innovations Group Other Current Receivables?

Surgical Innovations Group LSE:SUN Other Current Receivables is £0.12 Mil as of Dec. 2025. The stock has 2 warning signs investors should review.

Surgical Innovations Group's Other Current Receivables for the quarter that ended in Dec. 2025 was £0.12 Mil.

Surgical Innovations Group's quarterly Other Current Receivables stayed the same from Dec. 2024 (£0.00 Mil) to Jun. 2025 (£0.00 Mil) but then increased from Jun. 2025 (£0.00 Mil) to Dec. 2025 (£0.12 Mil).

Surgical Innovations Group's annual Other Current Receivables declined from Dec. 2023 (£0.01 Mil) to Dec. 2024 (£0.00 Mil) but then increased from Dec. 2024 (£0.00 Mil) to Dec. 2025 (£0.12 Mil).

Surgical Innovations Group Other Current Receivables Related Terms

Surgical Innovations Group Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Surgical Innovations Group's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Surgical Innovations Group Other Current Receivables Chart

Surgical Innovations Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 0.01 0.01 0.00 0.12

Surgical Innovations Group Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.00 0.00 0.00 0.12

Surgical Innovations Group Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of £0.12 Mil mean?
Surgical Innovations Group (LSE:SUN) has a Other Current Receivables of £0.12 Mil as of Dec. 2025. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Surgical Innovations Group and its competitors.
Is Surgical Innovations Group's Other Current Receivables too high?
Surgical Innovations Group's current Other Current Receivables is £0.12 Mil.
How does Surgical Innovations Group's Other Current Receivables compare to ABT and SYK?
Surgical Innovations Group's Other Current Receivables of £0.12 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Medical Devices & Instruments company?
A good Other Current Receivables depends on the Medical Devices & Instruments industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Surgical Innovations Group and its competitors. Surgical Innovations Group's current Other Current Receivables is £0.12 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Surgical Innovations Group stock overvalued right now?
Surgical Innovations Group (LSE:SUN) has a current Other Current Receivables of £0.12 Mil. The current Other Current Receivables is £0.12 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Surgical Innovations Group (LSE:SUN), the current Other Current Receivables is £0.12 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Surgical Innovations Group Business Description

Address Clayton Wood House, 6 Clayton Wood Bank, Leeds, GBR, LS16 6QZ
Surgical Innovations Group PLC is involved in the design, development, manufacture, and sale of devices for use in minimally invasive surgery (SI Brand), along with its label products through original equipment manufacturer (OEM) relationships, including precision engineering markets (PE). The Company's operating segments are SI Brand, OEM, and Distribution. The majority of its revenue is generated from the SI Brand segment, which is involved in the research, development, manufacture, and distribution of SI-branded minimally invasive devices. Geographically, the group derives a majority of its revenue from the United Kingdom, followed by Europe, the United States, the Asia-Pacific region, and the Rest of the world.